Agree Realty Partners with GlycoNex to Advance Gastric Cancer Treatment Research
- GlycoNex partners with Hokkaido University to advance gastric cancer treatment with their glycan-directed ADC, GNX1021.
- The collaboration enhances patient selection precision for GNX1021 by analyzing bLeB/Y expression alongside clinical biomarkers.
- GlycoNex aims to initiate Phase I clinical trials in 2026, expanding treatment options for gastric cancer patients.
Innovative Collaboration Targets Gastric Cancer Treatment
GlycoNex, Inc., a clinical-stage biotechnology firm based in New Taipei City, forges a strategic partnership with Hokkaido University Hospital to advance its promising glycan-directed antibody-drug conjugate (ADC), GNX1021, focused on treating gastric cancer. This collaboration responds to the pressing need for effective therapies in a region where gastric cancer ranks as the third most prevalent cancer and is projected to cause 39,900 deaths in Japan alone by 2024. The study will specifically analyze the expression of the branched Lewis B/Y (bLeB/Y) glycan antigen in gastric cancer patients, providing insights essential for identifying suitable candidates for GNX1021 treatment.
The collaboration aims to correlate bLeB/Y expression with established clinical biomarkers such as HER2, CLDN18, PD-L1, and MMR. This analysis is crucial as it enhances the precision of patient selection for GNX1021, which has shown notable tumor-suppressive properties in preclinical models, including those resistant to existing therapies. Dr. Mei-Chun Yang, CEO of GlycoNex, underscores the significance of this partnership in addressing unmet needs in oncology, particularly for patients who do not respond to HER2- and CLDN18-targeted therapies. The collaborative effort is expected to pave the way for innovative treatment strategies that could substantially improve patient outcomes.
With pre-fill and toxicology testing already completed, GlycoNex is poised for regulatory submissions in Taiwan and Japan, setting the stage to initiate Phase I clinical trials in 2026. This initiative is a critical step in expanding treatment options for gastric cancer patients, who currently face limited alternatives. GlycoNex's focus on glycan-directed ADCs and high-quality biosimilars positions the company as a frontrunner in the development of next-generation biologic therapies, potentially reshaping the landscape of gastric cancer treatment.
In addition to its collaboration with Hokkaido University, GlycoNex's innovative approach to glycan-directed therapies signifies a broader trend within the biopharmaceutical industry towards personalized medicine. By targeting specific molecular markers in cancer cells, companies like GlycoNex strive to enhance the efficacy of treatments while minimizing side effects, thus improving the quality of life for patients.
Related Cashu News

Lamar Advertising Co Moves to Value Indices Amid Shift in Investment Strategies
Lamar Advertising Co (Ticker: LAMR) has recently undergone a significant change in its market classification by being added to several Russell value and defensive indices. This inclusion reflects a sh…

Alexandria Real Estate Equities Advances Corporate Responsibility and Strengthens Its Position in Life Sciences
Alexandria Real Estate Equities (ARE) has made significant strides in enhancing its corporate responsibility efforts, as detailed in its recently published 2025 Corporate Responsibility Report. The re…

Healthpeak OP LLC Achieves Key Index Inclusion, Boosting Investor Interest and Trading Activity
Healthpeak OP LLC (Ticker: DOC) leverages significant market developments to reinforce its position in the real estate investment trust sector through strategic index inclusion, which may reshape inve…

Public Storage Boosts Financial Flexibility with New Credit Facility and Commercial Paper Program
Public Storage (Ticker: PSA) enhances its financial flexibility with a new unsecured credit facility and commercial paper program. Strategic Financial Innovations The company announces the closure of…

